| 6703- | DFC, | Molecular docking of anti-inflammatory drug diclofenac with metabolic targets: Potential applications in cancer therapeutics. |
| - | Analysis, | Var, | NA |
| 6704- | DFC, | Diclofenac demonstrates notable anticancer properties |
| - | Review, | Var, | NA |
| 6705- | DFC, | Development and Challenges of Diclofenac-Based Novel Therapeutics: Targeting Cancer and Complex Diseases |
| - | Review, | Var, | NA |
| 6706- | DFC, | MET, | Frontiers | Combined Metabolic Targeting With Metformin and the NSAIDs Diflunisal and Diclofenac Induces Apoptosis in Acute Myeloid Leukemia Cells |
| - | in-vitro, | AML, | U937 |
| 6707- | DFC, | Markers of mitochondrial dysfunction during the diclofenac-induced apoptosis in melanoma cell lines |
| - | in-vitro, | Melanoma, | NA |
| 6708- | DFC, | Repurposing Drugs as Expanding Cancer Treatment Palette: Diclofenac |
| 6709- | DFC, | Diclofenac induced apoptosis via altering PI3K/Akt/MAPK signaling axis in HCT 116 more efficiently compared to SW480 colon cancer cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Colon, | SW480 |
| 6688- | DFC, | New Aspects of an Old Drug – Diclofenac Targets MYC and Glucose Metabolism in Tumor Cells |
| - | in-vivo, | lymphoma, | U937 |
| 6697- | DFC, | Diclofenac induces apoptosis in hepatocytes by alteration of mitochondrial function and generation of ROS |
| 6696- | DFC, | MET, | Combined Modulation of Tumor Metabolism by Metformin and Diclofenac in Glioma |
| - | in-vitro, | GBM, | GBM |
| 6695- | DFC, | Inhibition of lactate dehydrogenase A by diclofenac sodium induces apoptosis in HeLa cells through activation of AMPK |
| - | in-vitro, | Cerv, | HeLa |
| 6694- | DFC, | Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent |
| - | Review, | Var, | NA |
| 6693- | DFC, | New aspects of an old drug--diclofenac targets MYC and glucose metabolism in tumor cells |
| - | vitro+vivo, | Var, | NA |
| 6692- | DFC, | Diclofenac Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer by Modulation of VEGF Levels and Arginase Activity |
| - | in-vivo, | PC, | Panc02 |
| 6691- | DFC, | Diclofenac impairs the proliferation and glucose metabolism of triple-negative breast cancer cells by targeting the c-Myc pathway |
| - | in-vitro, | Melanoma, | NA | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | HCC1937 | - | in-vitro, | BC, | MCF7 |
| 6690- | DFC, | Diclofenac: A Nonsteroidal Anti-Inflammatory Drug Inducing Cancer Cell Death by Inhibiting Microtubule Polymerization and Autophagy Flux |
| - | in-vitro, | Cerv, | HeLa |
| 6689- | DFC, | Diclofenac-Induced Apoptosis in the Neuroblastoma Cell Line SH-SY5Y: Possible Involvement of the Mitochondrial Superoxide Dismutase |
| - | in-vitro, | neuroblastoma, | SH-SY5Y |
| 6698- | DFC, | Diclofenac induces proteasome and mitochondrial dysfunction in murine cardiomyocytes and hearts |
| - | in-vivo, | Nor, | NA |
| 6687- | DFC, | Diclofenac-containing medicines - referral |
| - | Review, | Nor, | NA |
| 1886- | DFC, | Regulation of colonic epithelial butyrate transport: Focus on colorectal cancer |
| - | Review, | CRC, | NA |
| 6666- | DFE, | The impact of date palm fruits and their component polyphenols, on gut microbial ecology, bacterial metabolites and colon cancer cell proliferation |
| - | in-vitro, | Colon, | Caco-2 |
| 6663- | DFE, | Nutraceuticals of Phoenix dactylifera L.: Physicochemistry, Nutritional Value and Therapeutic Potential |
| - | Review, | Nor, | NA | - | Review, | AD, | NA |
| 6664- | DFE, | Anticancer Properties of Different Varieties of Date Palm (Phoenix dactylifera L.) Leaf Extracts in Human Tumor Cells: a Comparative Study |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | GBM, | U87MG |
| 6665- | DFE, | Cytotoxic Effect of Phoenix dactylifera (Iraqi Date) Leaves and Fruits Extracts against Breast Cancers Cell Lines |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | CAL51 | - | in-vitro, | BC, | MCF7 |
| 6667- | DFE, | Immunostimulant effect of dates (Phoenix dactylifera) on humoral and cellular immunity cells and their functions |
| - | in-vivo, | Nor, | NA |
| 6668- | DFE, | AgNPs, | Saponin-Derived Silver Nanoparticles from Phoenix dactylifera (Ajwa Dates) Exhibit Broad-Spectrum Bioactivities Combating Bacterial Infections |
| - | in-vitro, | Lung, | A549 |
| 4456- | DFE, | Induction of apoptosis and cell cycle arrest by ethyl acetate fraction of Phoenix dactylifera L. (Ajwa dates) in prostate cancer cells |
| - | in-vitro, | Pca, | PC3 |
| 4455- | DFE, | Ajwa Date (Phoenix dactylifera L.) Extract Inhibits Human Breast Adenocarcinoma (MCF7) Cells In Vitro by Inducing Apoptosis and Cell Cycle Arrest |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | 3T3 |
| 4454- | DFE, | Cytostatic and Anti-tumor Potential of Ajwa Date Pulp against Human Hepatocellular Carcinoma HepG2 Cells |
| - | in-vitro, | Liver, | HepG2 |
| 7522- | DFE, | Diet rich in date palm fruits improves memory, learning and reduces beta amyloid in transgenic mouse model of Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 6745- | DHA, | Omega-3 fatty acid DHA induces ferroptosis in colorectal cancer patient-derived organoids and drug-tolerant cells |
| - | in-vitro, | CRC, | HT29 |
| 6746- | DHA, | Free docosahexaenoic acid promotes ferroptotic cell death via lipoxygenase dependent and independent pathways in cancer cells |
| - | vitro+vivo, | Pca, | PC3 | - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Colon, | HT29 | - | in-vitro, | Cerv, | HeLa |
| 6747- | DHA, | erastin, | ELOVL5 Regulates Ferroptosis in Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 6748- | DHA, | Docosahexaenoic acid enrichment of tumor phospholipid membranes increases tumor necroptosis in mice bearing triple negative breast cancer patient-derived xenografts |
| - | in-vivo, | BC, | NA |
| - | Trial, | BC, | NA |
| - | Trial, | BC, | NA |
| - | Trial, | BC, | NA |
| 6752- | DHA, | A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease |
| - | Trial, | BC, | NA |
| 6753- | DHA, | Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting (DHA-WIN) |
| 6754- | DHA, | Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial |
| - | Trial, | AD, | NA |
| 6755- | DHA, | Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers before the Onset of Dementia |
| - | Trial, | AD, | NA |
| 6756- | DHA, | Omega-3 Fatty Acids and Cognitive Function |
| - | Review, | AD, | NA |
| 6757- | DHA, | EPA, | Does the ratio of eicosapentaenoic acid to docosahexaenoic acid matter in cancer treatment? A systematic review of their effects on cachexia-related inflammation |
| - | Review, | Var, | NA |
| 6758- | DHA, | Chemo, | Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial |
| - | Trial, | BC, | NA |
| 6759- | DHA, | doxoR, | Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 |
| 6760- | DHA, | Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans |
| - | Trial, | Nor, | NA |
| 6761- | DHA, | Docosahexaenoic acid reduces resting blood pressure but increases muscle sympathetic outflow compared with eicosapentaenoic acid in healthy men and women |
| - | Trial, | Nor, | NA |
| 6762- | DHA, | EPA, | Long-Chain Omega-3 Fatty Acids Eicosapentaenoic Acid and Docosahexaenoic Acid and Blood Pressure: A Meta-Analysis of Randomized Controlled Trials |
| - | Review, | Nor, | NA |
| 1184- | DHA, | Syndecan-1-Dependent Suppression of PDK1/Akt/Bad Signaling by Docosahexaenoic Acid Induces Apoptosis in Prostate Cancer |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | NA, | NA |
| 1183- | DHA, | Docosahexaenoic acid inhibited the Wnt/β-catenin pathway and suppressed breast cancer cells in vitro and in vivo |
| - | in-vitro, | BC, | 4T1 | - | in-vitro, | BC, | MCF7 | - | in-vivo, | BC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid